BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Vitiligo clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for vitiligo: 39 (28 sponsors; 14 newly posted in the last 180 days, 1 stopped in the last 180 days; 9 new-entrant sponsors). Momentum score 35.9, rank 2 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 5, Phase 2 16, Phase 3 14, Phase 4 0, N/A 4.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Incyte Corporation INCY | 4 | P3 4 | 0 | 1 |
| AbbVie ABBV | 3 | NA 1, P3 2 | 1 | 0 |
| Pfizer PFE | 2 | P3 2 | 0 | 1 |
| Teva Branded Pharmaceutical Products R&D LLC | 2 | P1 1, P3 1 | 1 | 0 |
| Beijing InnoCare Pharma Tech Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Clinuvel, Inc. CUVL | 1 | P3 1 | 0 | 0 |
| Dermavon Holdings Limited new entrant | 1 | P3 1 | 1 | 0 |
| Minghui Pharmaceutical (Hangzhou) Ltd new entrant | 1 | P3 1 | 1 | 0 |
| Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. new entrant | 2 | P2 2 | 2 | 0 |
| Jiangsu HengRui Medicine Co., Ltd. | 2 | P2 2 | 0 | 1 |
| Jiangsu vcare pharmaceutical technology co., LTD | 2 | P2 2 | 1 | 0 |
| Target PharmaSolutions, Inc. TGT | 2 | NA 2 | 1 | 0 |
| CAGE Bio Inc. | 1 | P1 1 | 0 | 1 |
| Dren Bio | 1 | P1 1 | 0 | 1 |
| E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. new entrant | 1 | P2 1 | 1 | 1 |
| Edesa Biotech Inc. EDSA new entrant | 1 | P2 1 | 1 | 0 |
| Eli Lilly and Company LLY | 1 | P2 1 | 0 | 1 |
| Elixiron Immunotherapeutics (Hong Kong) Ltd. | 1 | P2 1 | 0 | 1 |
| Forte Biosciences, Inc. | 1 | P1 1 | 0 | 1 |
| Hudson Biotech | 1 | P2 1 | 0 | 1 |
| Idorsia Pharmaceuticals Ltd. new entrant | 1 | P2 1 | 1 | 0 |
| Innovent Biologics (Suzhou) Co. Ltd. | 1 | P1 1 | 0 | 0 |
| InventisBio Co., Ltd new entrant | 1 | P2 1 | 1 | 0 |
| Novartis Pharmaceuticals NVS | 1 | P2 1 | 0 | 0 |
New-entrant sponsors: Dermavon Holdings Limited, Minghui Pharmaceutical (Hangzhou) Ltd, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., Genrix (Shanghai) Biopharmaceutical Co., Ltd., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Edesa Biotech Inc., Idorsia Pharmaceuticals Ltd., InventisBio Co., Ltd.
Recently stopped trials
- NCT06113328 Merck Sharp & Dohme LLC - terminated: Business Reasons A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-31 est. | P2 | Elixiron Immunotherapeutics (Hong Kong) Ltd. | NCT07223229 Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients | Non-segmental Vitiligo | recruiting | 45 |
| 2026-12-31 est. | P2 | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | NCT07712523 A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subj | Adult Subjects With Non-Segmental Vitiligo | recruiting | 200 |
| 2027-02-14 est. | P2 | Hudson Biotech | NCT07437560 Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo | NonSegmental Vitiligo; Nonsegmental Vitiligo (Stable) | recruiting | 60 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| None found. | ||||||
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "vitiligo"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.